Long-term Follow-up Study of BHC001 for TDT
ConditionThalassemia, Beta
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-35
SponsorBioray Laboratories
About this trial
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Eligibility criteria
Qualifiers
Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Assessments
Treatment groups
6 Participants
are divided into 1 treatment groupLocations
2The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army530021, NanningGuangxi, China
Xiangya Hospital of Central South University510510, ChangshaHunan, China
Sponsors and collaborators
Bioray Laboratories
Lead sponsor
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Collaborator
Xiangya Hospital of Central South University
Collaborator
Source ClinicalTrials.gov